Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
35 Results for "
PLK3
" in MedChemExpress (MCE) Product Catalog:
Products (35)
35 Results for "PLK3" in MCE Product Catalog:
Cat. No.: HY-172364
Target:
Research Areas:
PLK1-IN-12 is a highly selective and orally active PLK1 inhibitor with an IC50 of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC50: >10000 nM) and PLK3 (IC50: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research .
Cat. No.: HY-173212
CAS No.: 3038489-48-1
Target:
Research Areas:
PLK1-IN-13 is a selective and orally active PLK1 inhibitor (IC50: 0.27 nM). PLK1-IN-13 also inhibits PLK2 (IC50: 12.72 nM) and PLK3 (IC50: 4.12 nM). PLK1-IN-13 arrests cell at G2 phase, induces apoptosis and down-regulates the transcription of the proliferation-related oncogene c-MYC. PLK1-IN-13 inhibits tumor growth, and can be used for research of acute myeloid leukemia (AML) .
Cat. No.: HY-183965
Target:
Research Areas:
PLK3-IN-1 is a selective Polo-like kinase 3 (PLK3) inhibitor with a human PLK3 IC50 of 5 nM. PLK3-IN-1 can be used for cancer research .
Cat. No.: HY-15160C
CAS No.: 2108449-45-0
Target:
Research Areas:
TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .
Cat. No.: HY-N15384
CAS No.: 148180-61-4
Category:
Apocynaceae Flavonoids Wrightia arborea (Dennst.) Mabb. Plants Other Flavonoids Isoflavones
Target:
Cat. No.: HY-P702889
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PLK3; Proliferation-Related Kinase; Prev. CNK; Polo-Like Kinase 3; FNK; PLK-3; PRK; Polo-Like Kinase 3 (Drosophila); Cytokine-Inducible Serine/Threonine-Protein Kinase; Cytokine-Inducible Kinase; Serine/Threonine-Protein Kinase PLK3; Polo Like Kinase 3; F
Species:
Human
Source:
E. coli
Cat. No.: HY-P705596
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PLK3; Proliferation-Related Kinase; Prev. CNK; Polo-Like Kinase 3; FNK; PLK-3; PRK; Polo-Like Kinase 3 (Drosophila); Cytokine-Inducible Serine/Threonine-Protein Kinase; Cytokine-Inducible Kinase; Serine/Threonine-Protein Kinase PLK3; Polo Like Kinase 3; F
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-184863
CAS No.: 1034617-66-7
Target:
Research Areas:
PLK1-IN-17 is a potent PLK1 inhibitor with an IC50 of 2 nM. PLK1-IN-17 shows high selectivity for PLK2 and CDK2/A, moderate selectivity for PLK3, only weak activity against CK2, FLT3 and NEK6, and no activity against PDGFR, ALK and another 37 kinases. PLK1-IN-17 inhibits the proliferation of ovarian cancer cells and can be used in ovarian cancer-related research .
Cat. No.: HY-111090
CAS No.: 929095-23-8
Target:
Research Areas:
GSK461364 analogue 1 is a thiophene-based PLK1 inhibitor with a PLK1 IC50 of 2 nM and a PLK3 IC50 of 630 nM. GSK461364 analogue 1 also acts as an inhibitor of Nek2 kinase (IC50: 21 nM). GSK461364 analogue 1 has a solubility of ≥190 μM in pH 7.4 PBS and a human plasma protein binding rate of 91.5%. GSK461364 analogue 1 can be used in studies related to colon cancer, lung cancer, breast cancer and ovarian cancer .
Cat. No.: HY-181051
CAS No.: 3068378-51-5
Target:
Research Areas:
PLK1-IN-16 is a selective polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.25 nM. PLK1-IN-16 exhibits lower inhibitory potency against PLK2 and PLK3, induces G2 phase cell cycle arrest, induces apoptosis, and exhibits antiproliferative activity against tumor cells. PLK1-IN-16 can be stable under simulated gastric acid environmental conditions, and acceptable CYP 450 inhibition. PLK1-IN-16 can be used for the study of triple-negative breast cancer (TNBC), breast cancer, leukemia .
Cat. No.: HY-11003R
CAS No.: 660868-91-7
Synonyms: GW843682 (Standard)
Research Areas:
GW843682X (Standard) is the analytical standard of GW843682X (HY-11003). This product is intended for research and analytical applications. GW843682X is a selective, ATP-competitive inhibitor of PLK1 and PLK3, with IC50s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against ～30 other Kinases.
Cat. No.: HY-188141
CAS No.: 3057557-03-3
Target:
Research Areas:
Allopole-A is a Plk1 inhibitor with an IC50 of 1.4-2.5 μM against human Plk1 PBD1. Allopole-A binds to the allosteric W-F pocket in Plk1 PBD1, displacing the L2 loop, thereby disrupting water-mediated phospho-ligand binding interactions and promoting inhibitory interactions between the kinase domain and PBD to suppress Plk1 kinase activity. Allopole-A can be used in studies of human cancers with plk1 overexpression .
Cat. No.: HY-W162436
CAS No.: 29115-34-2
Research Areas:
MCC1019 is a selective PLK1 PBD inhibitor with an IC50 of 16.4 μmol/L. MCC1019 inactivates the AKT signaling pathway in cancer cells, and induces Apoptosis, Necroptosis and Autophagy. MCC1019 exhibits anticancer activity against lung cancer and prostate cancer .
Cat. No.: HY-187593
CAS No.: 1186496-84-3
Target:
Research Areas:
PLHSpT is an inhibitor of the Polo-box domain (PBD) of Polo-like kinase 1 (Plk1), with an IC50 of 36 μM. It binds to the PB1-PB2 cleft of the Plk1 PBD to block its interaction with phosphoprotein substrates, thereby inducing mitotic arrest and apoptosis in tumor cells. PLHSpT exerts antiglioma effects when delivered via liposomes, and it is applicable to research on glioblastoma multiforme and other human cancers [3].
Cat. No.: HY-183427
CAS No.: 2660138-04-3
Target:
Research Areas:
KBJK557 is a Plk1 PBD inhibitor with a human-derived IC50 value of 3.05 μM. KBJK577 binds to Plk1 PBD through electrostatic interactions, π-π stacking, hydrogen bonds, salt bridges and hydrophobic interactions, thereby disrupting the subcellular localization and function of Plk1. KBJK557 induces mitotic arrest, S-phase delay, G2/M-phase arrest and apoptosis, and inhibits cancer cell proliferation. KBJK557 can be used in research related to cancer and non-small cell lung cancer [3] .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
